Multi-Layer Distributed Storage of LHD Plasma Diagnostic Database

At the end of LHD experimental campaign in 2003, the amount of whole plasma diagnostics raw data had reached 3.16 GB in a long-pulse experiment. This is a new world record in fusion plasma experiments, far beyond the previous value of 1.5 GB/shot. The total size of the LHD diagnostic data is about 21.6 TB for the whole six years of experiments, and it continues to grow at an increasing rate. The LHD diagnostic database and storage system, i.e. the LABCOM system, has a completely distributed architecture to be sufficiently flexible and easily expandable to maintain integrity of the total amount of data. It has three categories of the storage layer: OODBMS volumes in data acquisition servers, RAID servers, and mass storage systems, such as MO jukeboxes and DVD-R changers. These are equally accessible through the network. By data migration between them, they can be considered a virtual OODB extension area. Their data contents have been listed in a “facilitator” PostgreSQL RDBMS, which now contains about 6.2 million entries, and informs the optimized priority to clients requesting data. Using the “glib” compression for all of the binary data and applying the three-tier application model for the OODB data transfer/retrieval, an optimized OODB read-out rate of 1.7 MB/s and effective client access speed of 3?25 MB/s have been achieved. As a result, the LABCOM data system has succeeded in combination of the use of RDBMS, OODBMS, RAID, and MSS to enable a virtual and always expandable storage volume, simultaneously with rapid data access

Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis

Summary: Baseline serum PINP value was significantly and independently associated with the increased bone mineral density (≥ 3%) in both total hip and femoral necks by 12 months of romosozumab treatment in patients with treatment-naive postmenopausal osteoporosis. Purpose: Some patients fail to obtain a sufficiently increased hip bone mineral density (BMD) by romosozumab (ROMO) treatment. This study aimed to investigate the prognostic factor for increased hip BMD with ROMO in patients with treatment-naive postmenopausal osteoporosis. Methods: This prospective, observational, and multicenter study included patients (n = 63: mean age, 72.6 years; T-scores of the lumbar spine [LS], − 3.3; total hip [TH], − 2.6; femoral neck [FN], − 3.3; serum type I procollagen N-terminal propeptide [PINP], 68.5 µg/L) treated by ROMO for 12 months. BMD and serum bone turnover markers were evaluated at each time point. A responder analysis was performed to assess the patient percentage, and both univariate and multivariate analyses were performed to investigate the factors associated with clinically significant increased BMD (≥ 3%) in both TH and FN. Results: Percentage changes of BMD from baseline in the LS, TH, and FN areas were 17.5%, 4.9%, and 4.3%, respectively. In LS, 96.8% of patients achieved ≥ 6% increased LS-BMD, although 57.1% could not achieve ≥ 3% increased BMD in either TH or FN. Multiple regression analysis revealed that only the baseline PINP value was significantly and independently associated with ≥ 3% increased BMD in both TH and FN (p = 0.019, 95% confidence interval = 1.006–1.054). The optimal cut-off PINP value was 53.7 µg/L with 54.3% sensitivity and 92.3% specificity (area under the curve = 0.752). Conclusions: In a real-world setting, baseline PINP value was associated with the increased BMD of TH and FN by ROMO treatment in treatment-naive patients.This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s00198-022-06642-1Kashii M., Kamatani T., Nagayama Y., et al. Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis. Osteoporosis International 34, 563 (2023

Nonstop Lose-Less Data Acquisition and Storing Method for Plasma Motion Images

Plasma diagnostic data analysis often requires the original raw data as they are, in other words, at the same frame rate and resolution of the CCD camera sensor. As a non-interlace VGA camera typically generates over 70 MB/s video stream, usual frame grabber cards apply the lossy compression encoder, such as mpeg-1/-2 or mpeg-4, to drastically lessen the bit rate. In this study, a new approach, which makes it possible to acquire and store such the wideband video stream without any quality reduction, has been successfully achieved. Simultaneously, the real-time video streaming is even possible at the original frame rate. For minimising the exclusive access time in every data storing, it has adopted the directory structure to hold every frame files separately, instead of one long consecutive file. The popular ‘zip’ archive method improves the portability of data files, however, the JPEG-LS image compression is applied inside by replacing its intrinsic deflate/inflate algorithm that has less performances for image data

Adaptive data migration scheme with facilitator database and multi-tier distributed storage in LHD

Recent “data explosion” induces the demand for high flexibility of storage extension and data migration. The data amount of LHD plasma diagnostics has grown 4.6 times bigger than that of three years before. Frequent migration or replication between plenty of distributed storage becomes mandatory, and thus increases the human operational costs. To reduce them computationally, a new adaptive migration scheme has been developed on LHD’s multi-tier distributed storage. So-called the HSM (Hierarchical Storage Management) software usually adopts a low-level cache mechanism or simple watermarks for triggering the data stage-in and out between two storage devices. However, the new scheme can deal with a number of distributed storage by the facilitator database that manages the whole data locations with their access histories and retrieval priorities. Not only the inter-tier migration but also the intra-tier replication and moving are even manageable so that it can be a big help in extending or replacing storage equipment. The access history of each data object is also utilized to optimize the volume size of fast and costly RAID, in addition to a normal cache effect for frequently retrieved data. The new scheme has been verified its effectiveness so that LHD multi-tier distributed storage and other next-generation experiments can obtain such the flexible expandability

Low serum albumin concentration is associated with increased risk of osteoporosis in postmenopausal patients with rheumatoid arthritis

Background: The risk of osteoporosis in patients with rheumatoid arthritis (RA) is frequently overlooked, and investigating a simple indicator in routine care may be beneficial to motivate osteoporosis examination. The aim of this retrospective, case-controlled study was to identify the correlation between serum albumin concentrations and the prevalence of osteoporosis in postmenopausal patients with RA. Methods: This study enrolled 197 patients who underwent dual-energy X-ray absorptiometry of lumbar spine (LS) and proximal femur without osteoporosis treatment [mean age, 67.5 years; disease duration, 12.8 years; Disease Activity Score assessing 28 joints with C-reactive protein, 2.0; prednisolone dose, 4.9 mg/day (usage, 42.6%); and LS T-score, −1.9]. Patients were classified into 2 groups: osteoporosis, defined as ≥ 1 part bone mineral density T-score ≤ −2.5 or history of fragility fracture of the vertebra or proximal femur (121 patients), and non-osteoporosis (76 patients). Groups were then matched by propensity score using clinical backgrounds affecting bone metabolism. Results: In non-matched model, serum albumin concentration was significantly associated with osteoporosis-related factors such as aging, inflammation, physical disability, and glucocorticoid dose. Multivariate logistic regression revealed that serum albumin concentration was independently and significantly associated with osteoporosis risk (odds ratio = 0.22, 95% confidence interval = 0.08, 0.61, p = 0.0033). After propensity score matching, 57 patients for each group showed that in addition to the LS and femoral neck T-scores (p < 0.001), serum albumin concentrations (p = 0.01) remained lower in the osteoporosis group compared to non-osteoporosis group. Receiver operating characteristic curve analysis in non-matched model revealed that when cut-off value of serum albumin concentration for indicating osteoporosis was set at 4.2 g/dl, the area under the curve was 0.69, sensitivity 0.74, and specificity 0.58. Conclusions: Low serum albumin concentration was significantly and independently associated with the prevalence of osteoporosis, which may be considered as one of the osteoporosis-related factors in postmenopausal patients with RA.Nagayama Y., Ebina K., Tsuboi H., et al. Low serum albumin concentration is associated with increased risk of osteoporosis in postmenopausal patients with rheumatoid arthritis. Journal of Orthopaedic Science 27, 1283 (2022); https://doi.org/10.1016/j.jos.2021.08.018

Investigation of turbulence in reversed field pinch plasma by using microwave imaging reflectometry

Turbulence in the reversed field pinch (RFP) plasma has been investigated by using the microwave imaging reflectometry in the toroidal pinch experiment RX (TPE-RX). In conventional RFP plasma, the fluctuations are dominated by the intermittent blob-like structures. These structures are accompanied with the generation of magnetic field, the strong turbulence, and high nonlinear coupling among the high and low k modes. The pulsed poloidal current drive operation, which improves the plasma confinement significantly, suppresses the dynamo, the turbulence, and the blob-like structures.This work is supported by the NINS Imaging Science Project (Grant No. NIFS08KEIN0021), SOKENDAI (Grant No. NIFS08GLPP003), and the Budget for Nuclear Research of the Ministry of Education, Culture, Sports, Science and Technology of Japan

The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab

Objectives: Tocilizumab (TCZ) shows good retention in patients with rheumatoid arthritis (RA), but no previous reports demonstrated hopeful treatment options against inadequate response to TCZ. Tacrolimus (TAC) has proved to show efficacy against inadequate response to tumor necrosis factor alpha inhibitors, yet its add-on effects on TCZ remain unknown. Methods: Twenty patients with RA (17 women, age 58.6 years, disease duration 12.1 years, prior TCZ duration 2.6 years, 18 intravenous [8 mg/kg/month] and 2 subcutaneous [324 mg/month] TCZ treatments, methotrexate 6.1 mg/week [70.0%]) who showed an inadequate response to TCZ (clinical disease activity index [CDAI] ≥ 5.8, 18 secondary non-responders) were additionally treated with TAC (1.1 mg/day), and enrolled in this 24-week, prospective study. Results: Seventeen patients (85.0%) continued the treatment for 24 weeks. Statistically significant decreases in outcome measures were as follows: disease activity score based on 28 joints with C-reactive protein (DAS28-CRP) from 3.3 at baseline to 2.1 at week 24 (p < 0.001), CDAI from 17.7 to 7.6 (p < 0.001), and serum matrix metalloproteinase-3 levels from 232.8 to 66.2 ng/ml (p < 0.001). About 15 patients (75%) achieved low disease activity or remission (DAS28-CRP ≤2.7 or CDAI ≤10) at week 24. Conclusions: Adding low-dose TAC to inadequate responders to TCZ may be a promising complementary treatment option.Kaneshiro S., Ebina K., Hirao M., et al. The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab. Modern Rheumatology 27, 42 (2017); https://doi.org/10.1080/14397595.2016.1181315

Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis

Purpose: To investigate the effects of prior treatment and the predictors of early treatment response to romosozumab (ROMO) in patients with postmenopausal osteoporosis. Methods: In this prospective, observational, multicenter study, 130 treatment-naïve patients (Naïve; n = 37) or patients previously treated with bisphosphonates (BP; n = 33), denosumab (DMAb; n = 45), or teriparatide (TPTD; n = 15) (age, 75.0 years; T-scores of the lumbar spine [LS] −3.2 and femoral neck [FN] −2.9) were switched to ROMO based on their physician's decision. Bone mineral density (BMD) and serum bone turnover markers were evaluated for six months. Results: At six months, LS BMD changes were 13.6%, 7.5%, 3.6%, and 8.7% (P <.001 between groups) and FN BMD changes were 4.2%, 0.4%, 1.6%, and 1.5% (P =.16 between groups) for Naïve, BP, DMAb, and TPTD groups, respectively. Changes in N-terminal type I procollagen propeptide (PINP; μg/L) levels from baseline → one month were 72.7 → 139.0, 33.5 → 85.4, 30.4 → 54.3, and 98.4 → 107.4, and those of isoform 5b of tartrate-resistant acid phosphatase (TRACP-5b) (mU/dL) were 474.7 → 270.2, 277.3 → 203.7, 220.3 → 242.0, and 454.1 → 313.0 for Naïve, BP, DMAb, and TPTD groups, respectively. Multivariate regression analysis revealed that significant predictors of LS BMD change at six months were prior treatment difference (r = −3.1, P =.0027) and TRACP-5b percentage change (r = −2.8, P =.0071) and PINP value at one month (r = 3.2, P =.0021). Conclusion: Early effects of ROMO on the increase in LS BMD are significantly affected by the difference of prior treatment and are predicted by the early change in bone turnover markers. Mini abstract: Early effects of ROMO on the increase in LS BMD at six months is significantly affected by the difference of prior treatment and also predicted by the early change of bone turnover markers in patients with postmenopausal osteoporosis.Ebina K., Hirao M., Tsuboi H., et al. Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. Bone 140, 115574 (2020); https://doi.org/10.1016/j.bone.2020.115574